H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy
H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix (OCUL) with a $25.00 price target, citing undervaluation. The stock is near its 52-week low at $6.29. The firm addressed EyePoint Pharmaceuticals' failed trial, noting differences in drug pharmacology and trial design. UBS initiated coverage with a Buy rating, projecting $3.3B in sales by 2035. RBC Capital reiterated its Outperform rating. OCUL plans to submit an NDA for Axpaxli in Q4 2026.
How this was made
The 30-second read
Why it matters
The reiteration of a Buy rating with a high price target could trigger short‑term buying pressure.
Market read
Analyst upgrade may provide a modest trading edge for OCUL.
What to watch
Potential delays in FDA approval could temper upside.
Background
Analyst coverage update for a micro‑cap ophthalmology company amid competitor trial news.
Ticker impact
H.C. Wainwright reiterated a Buy rating and $25 price target for Ocular Therapeutix, noting recent trial setbacks for a competitor and upcoming NDA filing.
likely upward pressure as investors price in the higher target and upcoming NDA.
Analyst upgrade with a substantial price target can attract new capital, especially with a pending FDA filing.
Market effects
May lift sentiment in the ophthalmology biotech sub‑sector.
Limited to US biotech investors.
Low
Counterpoint
The rating may be overly optimistic given the competitive setback and clinical risk.
Key entities
- companyOcular Therapeutix
NASDAQ‑listed biotech developing retinal therapies.
- analyst_firmH.C. Wainwright
Equity research firm issuing the rating.
